Neuronetics STIM Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Gross Profit by Business | ||||||
| Medical Device | $45.62M-0.2% | $45.72M-22.1% | $58.69M+5.6% | $55.59M+11.2% | $50.01M-5.5% | |
| Operating Income by Business | ||||||
| Medical Device | $15.6M+10.5% | $14.12M— | —— | —— | —— | |
| Research And Development Expense by Business | ||||||
| Medical Device | $7.4M-3.4% | $7.66M-40.9% | $12.96M-3.0% | $13.36M-1.2% | $13.52M+6.0% | |
| Revenue by Product | ||||||
| Clinic Revenue | $89.85M+3.3% | $86.98M+34.6% | $64.6M+47.1% | $43.91M+99.6% | $21.99M+395% | |
| Neuro Star Advanced Therapy System | $15.77M+1.5% | $15.54M+5.1% | $14.79M-2.6% | $15.18M-2.3% | $15.54M-3.5% | |
| Treatment Sessions | $43.89M-1.2% | $44.41M-0.5% | $44.64M-5.6% | $47.3M-1.6% | $48.05M-6.6% | |
| Concentration Risk % by Product | ||||||
| Neuro Star Advanced Therapy System | 130%-13.0pp | 143%+2.0pp | 141%-10.0pp | 151%+20.0pp | 131%-19.0pp | |
| Treatment Sessions | 224%+19.0pp | 205%— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Neuronetics break its business down?
- Neuronetics (STIM) reports revenue by business across 2 parts — Clinical Services and Medical Device. Each is extracted from the segment footnotes and tracked over time.
- Where does Neuronetics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Neuronetics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
